To Evaluate the Bioavailability of a Tablet of AZD1656

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Type 1 Diabetes

Treatments: Drug: AZD1656

Study type: Interventional

Funder types: Industry

Identifiers

NCT00817505

D1020C00010

Details and patient eligibility

About

To evaluate the bioavailability of a tablet of AZD1656.

Enrollment: 11 patients

Sex: All

Ages: 20 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female, type I diabetes patients, female with non child-bearing potential.
• Treated with insulin for more than 3 years. Well controlled HbA1c.
• Have a body mass index (BMI) ≥19 and ≤35

Exclusion criteria

• Clinically significant illness except type I diabetes, or clinically relevant trauma, as judged by the investigator, within 2 weeks before the first administration of the investigational product
• Daily use of nicotine containing substances.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

11 participants in 3 patient groups

1

Active Comparator group

Description:

AZD1656 tablet + food

Treatment:

Drug: AZD1656

Drug: AZD1656

2

Active Comparator group

Description:

AZD1656 susp. without food

Treatment:

Drug: AZD1656

Drug: AZD1656

3

Active Comparator group

Description:

AZD1656 tablet

Treatment:

Drug: AZD1656

Drug: AZD1656